Comparative Pharmacology
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HYDROCHLORIDE.
VANCOCIN HYDROCHLORIDE vs VANCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing polymerization and cross-linking of peptidoglycan.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the pentapeptide precursor, preventing transpeptidation and polymerization of peptidoglycan.
15-20 mg/kg IV every 8-12 hours; maximum single dose 2 g. Target trough 10-20 mcg/mL.
1-2 g IV every 12 hours; adjust based on trough concentrations (target 10-20 mcg/mL).
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
4-6 hours in adults with normal renal function; prolonged up to 7 days in anuria. Half-life inversely correlates with creatinine clearance.
Primarily renal (glomerular filtration): 80-90% of dose excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Renal: 80-90% unchanged via glomerular filtration; minor biliary (up to 5%) and fecal elimination.
Category C
Category A/B
Glycopeptide Antibiotic
Glycopeptide Antibiotic